Acadia Pharmaceuticals: Another Bite At The Alzheimer's Apple (NASDAQ:ACAD)
· seekingalpha.com
Acadia (ACAD) eyes Phase 2 remlifanserin Alzheimer’s psychosis results by September/October. Learn about the risks and revenue cushion from Daybue/Nuplazid.
Acadia ( ACAD ) plans to announce its phase 2 trial results for its drug candidate remlifanserin for the treatment of Alzheimer’s disease psychosis in Septemb...